|
|
Advances and Prospects of mRNA Vaccines Used in the Prevention and Therapies of Diseases |
Yu WANG,Yue-qiu BAI,Yi-xiao TIAN,Xin-yue WANG,Qing-sheng HUANG*() |
Northwestern Polytechnical University, School of Life Sciences, Xi’an 710072, China |
|
|
Abstract Nucleic acid vaccine based on messenger RNA (mRNA) is a kind of mRNA technology emerging in recent years. mRNA vaccines have many advantages over traditional vaccines, which can be manufactured in a cell-free manner, enabling rapid, economical and efficient production. In addition, single mRNA vaccines can encode multiple antigens, enhance the immune response against certain pathogens, improve the efficiency of treatment process of diseases, and can target multiple microbial or viral variants in a single formulation. mRNA is seen as a revolutionary vaccine technology in COVID-19 prevention and control, which has been developed and successfully applied in record time. The mRNA vaccine is with poor stability, so the development and applications of novel delivery systems are essential. With the intensive study of pharmacology of mRNA vaccines, the clinical applications of mRNA vaccines enter into a new stage. Recently, mRNA technologies were used in the prevention and therapies of diseases, and some results were published. Here, the output of mRNA vaccines used in prevention and therapies of diseases was summarized, and the development of mRNA vaccines was also discussed.
|
Received: 26 June 2022
Published: 04 November 2022
|
|
Corresponding Authors:
Qing-sheng HUANG
E-mail: huangqingsheng@nwpu.edu.cn
|
|
|
[1] |
陈彦, 孙英. mRNA疫苗研究进展:2021年拉斯克奖临床医学研究奖. 首都医科大学学报, 2021, 42(5): 893-899.
|
|
|
[1] |
Chen Y, Sun Y. Progress in mRNA vaccine:the 2021 lasker clinical medicine research award. Journal of Capital Medical University, 2021, 42(5): 893-899.
|
|
|
[2] |
Chaudhary N, Weissman D, Whitehead K A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 2021, 20(11): 817-838.
doi: 10.1038/s41573-021-00283-5
pmid: 34433919
|
|
|
[3] |
Oh S, Kessler J A. Design, assembly, production, and transfection of synthetic modified mRNA. Methods, 2018, 133: 29-43.
doi: S1046-2023(17)30315-8
pmid: 29080741
|
|
|
[4] |
Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics, 2020, 12(2): 102.
doi: 10.3390/pharmaceutics12020102
|
|
|
[5] |
Linares-Fernández S, Lacroix C, Exposito J Y, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends in Molecular Medicine, 2020, 26(3): 311-323.
doi: S1471-4914(19)30244-8
pmid: 31699497
|
|
|
[6] |
Ho W, Gao M Z, Li F Q, et al. Next-generation vaccines: nanoparticle-mediated DNA and mRNA delivery. Advanced Healthcare Materials, 2021, 10(8): 2001812.
|
|
|
[7] |
Dhaliwal H K, Fan Y F, Kim J, et al. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Molecular Pharmaceutics, 2020, 17(6): 1996-2005.
doi: 10.1021/acs.molpharmaceut.0c00170
pmid: 32365295
|
|
|
[8] |
Golob J L, Lugogo N, Lauring A S, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight, 2021, 6(9): e149187.
|
|
|
[9] |
Blakney A K, Zhu Y Q, McKay P F, et al. Big is beautiful: enhanced saRNA delivery and immunogenicity by a higher molecular weight, bioreducible, cationic polymer. ACS Nano, 2020, 14(5): 5711-5727.
doi: 10.1021/acsnano.0c00326
pmid: 32267667
|
|
|
[10] |
Abramson A, Kirtane A R, Shi Y H, et al. Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter, 2022, 5(3): 975-987.
doi: 10.1016/j.matt.2021.12.022
|
|
|
[11] |
Rayamajhi S, Wilson S, Aryal S, et al. Biocompatible FePO4 nanoparticles: drug delivery, RNA stabilization, and functional activity. Nanoscale Research Letters, 2021, 16(1): 169.
doi: 10.1186/s11671-021-03626-8
pmid: 34837559
|
|
|
[12] |
Ebinger J E, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nature Medicine, 2021, 27(6): 981-984.
doi: 10.1038/s41591-021-01325-6
pmid: 33795870
|
|
|
[13] |
Polack F P, Thomas S J, Kitchin N, et al. Safety and efficacy of the BNT162b 2 mRNA COVID-19 vaccine. The New England Journal of Medicine, 2020, 383(27): 2603-2615.
doi: 10.1056/NEJMoa2034577
|
|
|
[14] |
Baden L R, El Sahly H M, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine, 2021, 384(5): 403-416.
doi: 10.1056/NEJMoa2035389
pmid: 33378609
|
|
|
[15] |
Freyn A W, Ramos da Silva J, Rosado V C, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Molecular Therapy, 2020, 28(7): 1569-1584.
doi: S1525-0016(20)30199-4
pmid: 32359470
|
|
|
[16] |
Mu Z K, Haynes B F, Cain D W. HIV mRNA vaccines-progress and future paths. Vaccines, 2021, 9(2): 134.
doi: 10.3390/vaccines9020134
|
|
|
[17] |
Zhang P, Narayanan E, Liu Q B, et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27(12): 2234-2245.
doi: 10.1038/s41591-021-01574-5
pmid: 34887575
|
|
|
[18] |
Taylor L H, Hampson K, Fahrion A, et al. Difficulties in estimating the human burden of canine rabies. Acta Tropica, 2017, 165: 133-140.
doi: S0001-706X(15)30184-4
pmid: 26721555
|
|
|
[19] |
Schnee M, Vogel A B, Voss D, et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Neglected Tropical Diseases, 2016, 10(6): e0004746.
|
|
|
[20] |
Alberer M, Gnad-Vogt U, Hong H S, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. The Lancet, 2017, 390(10101): 1511-1520.
doi: 10.1016/S0140-6736(17)31665-3
|
|
|
[21] |
Stokes A, Pion J, Binazon O, et al. Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats. Regulatory Toxicology and Pharmacology, 2020, 113: 104648.
doi: 10.1016/j.yrtph.2020.104648
|
|
|
[22] |
Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Molecular Cancer, 2021, 20(1): 41.
doi: 10.1186/s12943-021-01335-5
pmid: 33632261
|
|
|
[23] |
Pang G B, Liu Y, Wang Y Y, et al. Endotoxin contamination in ovalbumin as viewed from a nano-immunotherapy perspective. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14(1): e1747.
|
|
|
[24] |
Islam M A, Rice J, Reesor E, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 2021, 266: 120431.
doi: 10.1016/j.biomaterials.2020.120431
|
|
|
[25] |
Meng C Y, Chen Z, Mai J H, et al. Virus-mimic mRNA vaccine for cancer treatment. Advanced Therapeutics, 2021, 4(11): 2100144.
|
|
|
[26] |
Tusup M, Läuchli S, Jarzebska N T, et al. mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma. Pharmaceutics, 2021, 13(7): 1040.
doi: 10.3390/pharmaceutics13071040
|
|
|
[27] |
Hewitt S L, Bailey D, Zielinski J, et al. Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2020, 26(23): 6284-6298.
doi: 10.1158/1078-0432.CCR-20-0472
|
|
|
[28] |
Hewitt S L, Bai A L, Bailey D, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Science Translational Medicine, 2019, 11(477): eaat9143.
|
|
|
[29] |
Huang X, Tang T Y, Zhang G, et al. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development. Molecular Cancer, 2021, 20(1): 50.
doi: 10.1186/s12943-021-01342-6
pmid: 33685460
|
|
|
[30] |
van Oosterwijk J G, Wikel S K. Resistance to ticks and the path to anti-tick and transmission blocking vaccines. Vaccines, 2021, 9(7): 725.
doi: 10.3390/vaccines9070725
|
|
|
[31] |
Künnapuu J, Bokharaie H, Jeltsch M. Proteolytic cleavages in the VEGF family: generating diversity among angiogenic VEGFs, essential for the activation of lymphangiogenic VEGFs. Biology, 2021, 10(2): 167.
doi: 10.3390/biology10020167
|
|
|
[32] |
Bourhis M, Palle J, Galy-Fauroux I, et al. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Frontiers in Immunology, 2021, 12: 616837.
|
|
|
[33] |
Gan L M, Lagerström-Fermér M, Carlsson L G, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nature Communications, 2019, 10: 871.
doi: 10.1038/s41467-019-08852-4
|
|
|
[34] |
Rurik J G, Tombácz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science, 2022, 375(6576): 91-96.
doi: 10.1126/science.abm0594
pmid: 34990237
|
|
|
[35] |
Hargadon K M, Johnson C E, Williams C J. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology, 2018, 62: 29-39.
doi: S1567-5769(18)30252-2
pmid: 29990692
|
|
|
[36] |
Welden J R, Stamm S. Pre-mRNA structures forming circular RNAs. Biochimica et Biophysica Acta Gene Regulatory Mechanisms, 2019, 1862(11-12): 194410.
|
|
|
[37] |
Qu L, Yi Z Y, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell, 2022, 185(10): 1728-1744.e16.
doi: 10.1016/j.cell.2022.03.044
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|